Why new Alzheimer's drugs don't work | Mike Greicius, Stanford University School of Medicine
In the past few years, Big Pharma has released not one, but three new treatments for Alzheimer’s disease.
Aducanemab (2021), Lecanemab (2023), and Donanemab (2024), are the first treatments to effectively clear the brain of amyloid plaques — the sticky protein clumps whose build-up in the brain has defined the disease for decades. The problem? They may not help patients at all.
Today’s guest, Stanford neurologist Mike Greicius, considers the new amyloid-clearing drugs a major disappointment — and worse, says they likely do more harm than good for patients.
Despite this critique, Greicius, thinks that the next few years will be an exciting time for novel Alzheimer’s therapies, as growing biological understanding of Alzheimer’s risk and resilience bear fruit with promising new approaches to treatment.
Learn More:
Greicius is the Iqbal Farrukh and Asad Jamal Professor of Neurology and Neurological Sciences at Stanford Medicine, and a member of the Knight Initiative for Brain Resilience and Alzheimer's Disease Research Center at Stanford University.
Amyloid Drug Skepticism:
- Substantial Doubt Remains about the Efficacy of Anti-Amyloid Antibodies
(Commentary, Journal of Alzheimer's Disease, 2024) - New Drug Approved for Early Alzheimer’s (New York Times, 2024)
- Alzheimer's drug adoption in US slowed by doctors' skepticism (Reuters, 2024)
- One step back: Why the new Alzheimer’s plaque-attack drugs don’t work (Stanford Medicine Scope Blog, 2024)
Alzheimer's Genetics Research:
- Knight-funded research uncovers gene mutations that may prevent Alzheimer’s Disease (Knight Initiative for Brain Resilience, 2024)
- Why is a common gene variant bad for your brain? (Stanford Medicine Magazine, 2024)
- Scientists find genetic Alzheimer’s risk factor tied to African ancestry (Stanford Medicine, 2023)
Episode Credits
This episode was produced by Michael Osborne, with production assistance by Morgan Honaker, and hosted by Nicholas Weiler. Art by Aimee Garza.
Thanks for listening! If you're enjoying our show, please take a moment to give us a review on your podcast app of choice and share this episode with your friends. That's how we grow as a show and bring the stories of the frontiers of neuroscience to a wider audience.
We want to hear from your neurons! Email us at at neuronspodcast@stanford.edu
Learn more about the Wu Tsai Neurosciences Institute at Stanford and follow us on Twitter, Facebook, and LinkedIn.
More description
In the past few years, Big Pharma has released not one, but three new treatments for Alzheimer’s disease.
Aducanemab (2021), Lecanemab (2023), and Donanemab (2024), are the first treatments to effectively clear the brain of amyloid plaques — the sticky protein clumps whose build-up in the brain has defined the disease for decades. The problem? They may not help patients at all.
Today’s guest, Stanford neurologist Mike Greicius, considers the new amyloid-clearing drugs a major disappointment — and worse, says they likely do more harm than good for patients.
Despite this critique, Greicius, thinks that the next few years will be an exciting time for novel Alzheimer’s therapies, as growing biological understanding of Alzheimer’s risk and resilience bear fruit with promising new approaches to treatment.
Learn More:
Greicius is the Iqbal Farrukh and Asad Jamal Professor of Neurology and Neurological Sciences at Stanford Medicine, and a member of the Knight Initiative for Brain Resilience and Alzheimer's Disease Research Center at Stanford University.
Amyloid Drug Skepticism:
- Substantial Doubt Remains about the Efficacy of Anti-Amyloid Antibodies
(Commentary, Journal of Alzheimer's Disease, 2024) - New Drug Approved for Early Alzheimer’s (New York Times, 2024)
- Alzheimer's drug adoption in US slowed by doctors' skepticism (Reuters, 2024)
- One step back: Why the new Alzheimer’s plaque-attack drugs don’t work (Stanford Medicine Scope Blog, 2024)
Alzheimer's Genetics Research:
- Knight-funded research uncovers gene mutations that may prevent Alzheimer’s Disease (Knight Initiative for Brain Resilience, 2024)
- Why is a common gene variant bad for your brain? (Stanford Medicine Magazine, 2024)
- Scientists find genetic Alzheimer’s risk factor tied to African ancestry (Stanford Medicine, 2023)
Episode Credits
This episode was produced by Michael Osborne, with production assistance by Morgan Honaker, and hosted by Nicholas Weiler. Art by Aimee Garza.
Thanks for listening! If you're enjoying our show, please take a moment to give us a review on your podcast app of choice and share this episode with your friends. That's how we grow as a show and bring the stories of the frontiers of neuroscience to a wider audience.
We want to hear from your neurons! Email us at at neuronspodcast@stanford.edu
Learn more about the Wu Tsai Neurosciences Institute at Stanford and follow us on Twitter, Facebook, and LinkedIn.
Listen elsewhere
Available Results
Generated results are saved to your library for reuse and search.